<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6329">
  <stage>Registered</stage>
  <submitdate>16/02/2017</submitdate>
  <approvaldate>16/02/2017</approvaldate>
  <nctid>NCT03062956</nctid>
  <trial_identification>
    <studytitle>A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491</studytitle>
    <scientifictitle>Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MYK-491-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dilated Cardiomyopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MYK-491 or placebo

Experimental: Single oral dose of MYK-491 - single-dose, oral suspension

Placebo Comparator: Single oral dose of placebo - single-dose, oral suspension


Treatment: drugs: MYK-491 or placebo
Oral suspension

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability assessments will include treatment emergent AEs and SAEs, ECG recordings, vital signs, hs-troponin 1 concentrations, laboratory abnormalities and physical exam abnormalities</outcome>
      <timepoint>7 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma drug concentration (Cmax)</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Tmax)</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve (AUC)</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>First-order terminal elimination half-life (t1/2)</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean retention time (MRT)</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Weight between 60 and 90 kg inclusive

          -  Resting heart rate of &lt; 80 beats per minute

          -  Documented LVEF greater than or equal to 55% during Screening

          -  Normal electrocardiogram (ECG) at Screening

          -  Normal acoustic windows on transthoracic echocardiograms at Screening

          -  All safety laboratory parameters within normal limits at Screening

          -  History or evidence of another clinically significant disorder, in the opinion of the
             investigator.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Active infection

          -  History of coronary artery disease

          -  History of malignancy with the exception of in situ cervical cancer more than 5 years
             prior to Screening or surgically-excised non-melanomatous skin cancers more than 2
             years prior to Screening

          -  Positive serology tests at screening

          -  Current use of tobacco or nicotine-containing products exceeding 10 per day.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>16/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>56</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/07/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MyoKardia, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Up to 56 healthy volunteers will be given a single dose of MYK-491 or placebo and be
      monitored for safety and tolerability over a 7 day period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03062956</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason Lickliter, MD</name>
      <address>Nucleus Network</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Chrishni Williams</name>
      <address />
      <phone />
      <fax />
      <email>C.Williams@nucleusnetwork.com.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>